Manejo práctico de los nuevos anticoagulantes orales en fibrilación auricular no valvular

Vista sencilla de ítem
dc.contributor.authorLaguado, Marlonspa
dc.contributor.authorArdila Acuña, Laura Yeseniaspa
dc.contributor.authorMayorga Quintero, Jairo Albertospa
dc.contributor.authorRangel Vera, Jully Andreaspa
dc.date.accessioned2020-10-27T14:19:21Z
dc.date.available2020-10-27T14:19:21Z
dc.date.issued2019-07-30
dc.description.abstractIntroducción. La fibrilación auricular es la arritmia más frecuente en la prácticaclínica, cuya incidencia viene en ascenso alcanzando el 8 % en edades que superanlos 80 años, con un impacto importante en la morbimortalidad relacionado conlas complicaciones cerebrovasculares. El objetivo es identificar los aspectosfarmacológicos y de manejo práctico de los nuevos anticoagulantes orales enpaciente con fibrilación auricular no valvular. División de los temas tratados. Se realizó una revisión bibliográfica no sistemáticaen bases de datos y bibliotecas electrónicas (PubMed, Cochrane, Lilacs) incluyendoartículos desde 2008 hasta 2019, en idioma inglés y español que contuvieran lostópicos de interés. Se realizó una descripción detallada de las generalidades de losanticoagulantes orales en fibrilación auricular, incluyendo dabigatrán, rivaroxabán,apixabán y edoxabán; monitorización de la actividad anticoagulante; descripcióndel manejo perioperatorio de los nuevos anticoagulantes orales y reversión de laanticoagulación para los nuevos anticoagulantes orales.Conclusiones. El uso de nuevos anticoagulantes orales en paciente con fibrilaciónauricular no valvular es una buena alternativa, con facilidad de administración oral,sin aumento significativo del riesgo de sangrado, comparado con warfarina, con laventaja de no requerir monitoría continua con paraclínicos.spa
dc.description.abstractenglishIntroduction. Atrial fibrillation is the most common arrhythmia in clinical practice. Itsincidence has been on the rise, reaching 8 % among those patients over the age of 80,with a significant impact on morbimortality related to cerebrovascular complications.The objective is to identify aspects of pharmacology and practical use of the new oralanticoagulants in patients with non-valvular atrial fibrillation.Division of topics covered. A non-systematic literature research was conducted indatabases and digital libraries (PubMed, Cochrane, Lilacs), including articles from2008 to 2019, both in English and in Spanish that included the topics of interest.A detailed description of the generalities of oral anticoagulants for atrial fibrillationwas made, including dabigatran, rivaroxaban, apixaban and edoxaban; monitoringanticoagulant activity; description of the perioperative use of new oral anticoagulantsand reversal of anticoagulation for the new oral anticoagulants.Conclusions. The use of new oral anticoagulants in patients with non-valvular atrialfibrillation is a good alternative, with easy oral administration, without significantincrease in the risk of bleeding, compared to warfarin, and with the advantage of notrequiring continuous paraclinical monitoring.eng
dc.format.mimetypeapplication/pdfspa
dc.format.mimetypeText/htmlspa
dc.identifier.doihttps://doi.org/10.29375/01237047.2823
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga UNABspa
dc.identifier.issn2382-4603
dc.identifier.issn0123-7047
dc.identifier.repourlrepourl:https://repository.unab.edu.co
dc.identifier.urihttp://hdl.handle.net/20.500.12749/9936
dc.language.isospaspa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/2823/3072
dc.relationHttps://revistas.unab.edu.co/index.php/medunab/article/view/2823/3084
dc.relation/*ref*/Deshpande S, Catanzaro J , Wann S. Atrial fibrillation prevalence and scope of the problem. Cardiac Electrophysiology Clinics. 2014; 6 (1):1 - 4. doi: 10.1016/j. ccep.2013.10.006 2. Renoux C, Patenaude V , Suissa S. Incidence, mortality, and sex differences of non-valvular atrial fibrillation: A population-based study. Journal of the American Heart Association. 2014; 3 (6):1 - 8. doi: 10.1161/ JAHA.114.001402 3. Mulpuru S, Rabinstein A, Asirvatham S. Atrial fibrillation and stroke a neurologic perspective. Cardiac Electrophysiology Clinics 2014; 6(1):31 - 41. doi: 10.1016/j.ccep.2013.11.001 4. Castellano JM, Chinitz J, Willner J, Fuster V. Mechanisms of stroke in atrial fibrillation. Cardiac Electrophysiology Clinics. 2014; 6(1):5 - 15. doi: 10.1016/j. ccep.2013.10.007. 5. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014; 130(23)201 -267. doi: 10.1161/ CIR.0000000000000041 6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016; 37(38):2893 - 2962. doi: 10.1093/eurheartj/ehw210 7. Harter K, Levine M, Henderson S. O. Anticoagulation drug therapy: a review. The Western Journal of Emergency Medicine. 2015; 16(1):11 - 7. doi: 10.5811/ westjem.2014.12.22933 8. Tatjana S, Gregory Y. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovascular. Hematological Agents in Medicinal Chemistry. 2014 ; 26 (2) :115 - 129. doi: 10.1016/j.beha.2013.07.008 9. Cove C, Hylek E. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. Journal of the American Heart Association. 2013; 2(5):115 - 219. doi: 10.1161/ JAHA.113.000136 10. Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2009; 361(12):1139 - 1151. doi: 10.1056/NEJMoa0905561 11. Hinojar R, Jiménez-Natcher J, Fernández-Golfín C, Zamorano J. New oral anticoagulants: a practical guide for physicians. European Heart Journal - Cardiovascular Pharmacotherapy. 2015; 1(2):134 - 145. doi: 10.1093/ehjcvp/pvv002 12. Ferns S, Naccarelli G. New Oral Anticoagulants. Their Role in Stroke Prevention in High-Risk Patients with Atrial Fibrillation. Medical Clinics of North America. 2015; 99(4):759 - 80. doi: 10.1016/j. mcna.2015.02.006 13. Shafeeq H , Tran T. New oral anticoagulants for atrial fibrillation: are they worth the risk? P&T : A Peer-Reviewed Journal for Formulary Management. [Internet]. 2014.[citado el 03 de Junio del 2019]; 39(1):54 - 64. Recuperado a partir de: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC3956385/ 14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine. 2011; 365(10):883-91. doi: 10.1056/NEJMoa1009638 15. López-Sendón J, Merino J. Resultados e implicaciones del estudio ROCKET. Revista Española de Cardiología Suplementos. 2013; 13(C):42 - 46. doi: 10.1016/S1131-3587(13)70058-X 16. Mekaj Y, Mekaj A, Duci S, Miftari E. New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and Clinical Risk Management. 2015(11):967 - 977. doi: 10.2147/TCRM.S84210 17. Shamoun F, Obeid H, Ramakrishna H. Novel anticoagulants in atrial fibrillation: Monitoring, reversal and perioperative management. BioMed Research International. 2015; 424031. doi: 10.1155/2015/424031 18. Steinberg B, Piccini, J. Anticoagulation in atrial fibrillation. British Medical Journal. 2014; 14(348) 2116. doi: 10.1136/bmj.g2116 19. Martínez-Rubio A, Martínez-Torrecilla R. Evidencias actuales de los nuevos anticoagulantes orales en el tratamiento de la fibrilación auricular no valvular: comparación de subestudios. Revista Espanola de Cardiologia. 2015; 68(3):185 - 189. doi: 10.1016/j. recesp.2014.07.017 20. Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Revista Española de Cardiología Suplementos. 2013; 13(1 SUPPL.3) 33 - 41. doi: 10.1016/S1131-3587(13)70057-8 21. Hanley C, Kowey P. Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?. Journal of Thoracic Disease. 2015; 7(2):165 - 171. doi: 10.3978/j.issn.2072-1439.2015.01.23 22. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 15(5):625 - 651. doi: 10.1093/europace/euv309 23. Bounameaux H, Camm AJ. Edoxaban: An update on the new oral direct factor Xa inhibitor. Drugs. 2014; 74(11):1209-1231. doi: http://dx.doi.org/10.1007/ s40265-014-0261-1 24. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient plasma samples. Thrombosis and Haemostasis. 2013 ; 110(2):308 - 315. doi: 10.1160/TH13-04-0301 25. Rechenmacher S, Fang, J. Bridging Anticoagulation Primum Non Nocere. Journal of the American College of Cardiology. 2015; 66(12):1392-13403. doi: 10.1016/j.jacc.2015.08.002 26. Díaz J, Duque M, Duque L, Uribe W, Medina E, Marín J. Tratamiento perioperatorio del paciente con antiagregación o anticoagulación. Revista Colombiana de Cardiología. 2012; 19(5): 252 - 259. doi: 10.1016/ S0120-5633(12)70141-9 27. Lai A, Davidson N, Galloway S, Thachil J. Perioperative management of patients on new oral anticoagulants. The British journal of surgery. 2014; 101(7): 742 - 9. doi: 10.1002/bjs.9485 28. Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and Vitamin K antagonists: A systematic review and me ta-Analysis. PLoS ONE. 2015; 10(9): e0137444. doi: 10.1371/journal.pone.0137444 29. Ansell J. Reversal Agents for the Direct Oral Anticoagulants. Hematology/Oncology Clinics of North America. 2016; 30(5): 1085-1098. doi: 10.1016/j. hoc.2016.05.006 30. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015; 373(25):2413-2424. doi: 10.1056/NEJMoa1510991 31. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. NEnglJMed. 2015; 373(6):511 - 520. doi: 10.1056/NEJMoa1502000 32. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. New England Journal of Medicine. 2014; 371(22):2141 - 2142. doi: 10.1056/NEJMc1411800 33. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019; 380(14):1326 - 1335. doi: 10.1056/NEJMoa1814051.
dc.relation.referencesDeshpande S, Catanzaro J , Wann S. Atrial fibrillation prevalence and scope of the problem. Cardiac Electro-physiology Clinics. 2014; 6 (1):1 - 4. doi: 10.1016/j.ccep.2013.10.006
dc.relation.referencesRenoux C, Patenaude V , Suissa S. Incidence, mortal-ity, and sex differences of non-valvular atrial fibrilla-tion: A population-based study. Journal of the Ameri-can Heart Association. 2014; 3 (6):1 - 8. doi: 10.1161/JAHA.114.001402
dc.relation.referencesMulpuru S, Rabinstein A, Asirvatham S. Atrial fibril-lation and stroke a neurologic perspective. Cardiac Electrophysiology Clinics 2014; 6(1):31 - 41. doi: 10.1016/j.ccep.2013.11.001
dc.relation.referencesCastellano JM, Chinitz J, Willner J, Fuster V. Mecha-nisms of stroke in atrial fibrillation. Cardiac Electro-physiology Clinics. 2014; 6(1):5 - 15. doi: 10.1016/j.ccep.2013.10.007.
dc.relation.referencesJanuary CT, Wann LS, Alpert JS, Calkins H, Cigar-roa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atri-al fibrillation: A report of the American College of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014; 130(23)201 -267. doi: 10.1161/CIR.0000000000000041
dc.relation.referencesKirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collab-oration with EACTS. European Heart Journal. 2016; 37(38):2893 - 2962. doi: 10.1093/eurheartj/ehw210
dc.relation.referencesHarter K, Levine M, Henderson S. O. Anticoagulation drug therapy: a review. The Western Journal of Emer-gency Medicine. 2015; 16(1):11 - 7. doi: 10.5811/westjem.2014.12.22933
dc.relation.referencesTatjana S, Gregory Y. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovascular. He-matological Agents in Medicinal Chemistry. 2014 ; 26 (2) :115 - 129. doi: 10.1016/j.beha.2013.07.008
dc.relation.referencesCove C, Hylek E. An updated review of target-specif-ic oral anticoagulants used in stroke prevention in atri-al fibrillation, venous thromboembolic disease, and acute coronary syndromes. Journal of the American Heart Association. 2013; 2(5):115 - 219. doi: 10.1161/JAHA.113.000136
dc.relation.referencesConnolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2009; 361(12):1139 - 1151. doi: 10.1056/NEJMoa0905561
dc.relation.urihttps://revistas.unab.edu.co/index.php/medunab/issue/view/249
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceMedUNAB; Vol. 22 Núm. 1 (2019): abril - julio 2019: Cáncer Colorrectal, Sensation Seeking, Anticoagulantes; 38-50
dc.subjectanticoagulantes
dc.subjectFibrilación auricular
dc.subjectDabigatran
dc.subjectRivaroxaban
dc.subjectAccidente cerebrovascular
dc.subject.keywordsanticoagulantseng
dc.subject.keywordsAtrial fibrillationeng
dc.subject.keywordsDabigatraneng
dc.subject.keywordsRivaroxabaneng
dc.subject.keywordsCerebrovascular accidenteng
dc.titleManejo práctico de los nuevos anticoagulantes orales en fibrilación auricular no valvular
dc.title.translatedPractical use of new oral anticoagulants in non-valvular atrial fibrillation
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversionInfo:eu-repo/semantics/publishedVersion
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localArtículospa
dc.type.redcolhttp://purl.org/redcol/resource_type/ART

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
2019_Manejo_práctico.pdf
Tamaño:
619.94 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar

Colecciones

Revista MedUNAB